FGF23 and chronic kidney disease: Thus, the use of ESAs in the treatment of CKD may provide benefit in terms of mineral metabolism, as previous work using iron injections alone in a rat model of CKD did not have major effects on plasma FGF23 levels (Gravesen, Hofman‐Bang, Mace, Lewin, & Olgaard, 2013).